Clin2
NCT03943238Possibly a fitRecruiting

Kidney transplant with immune therapy to prevent rejection

Living Donor Kidney Transplantation

Part of Blood & lymphatic, Kidney & urinary clinical trials.

This trial tests a combination of low-dose radiation, chemotherapy, and donor immune cells to help your body accept a living donor kidney without long-term anti-rejection drugs.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
22 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You are getting a kidney from a living donor who is a relative or a close match.
  • You agree to use birth control for at least 1 year after transplant.
  • You have never had an organ transplant before.
  • You do not have active infections like HIV, hepatitis B, or hepatitis C.
  • You have no history of cancer except for certain skin cancers.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03591302Recruiting· Phase 1
Stem cell transplant to stop anti-rejection drugs after kidney transplant

This study tries to use a stem cell transplant from your original kidney donor to help your body accept the kidney without needing lifelong anti-rejection drugs. You must have a perfectly matched sibling donor who is still available.

Palo Alto, California
NCT04571203Recruiting· Phase 1
Kidney transplant plus blood-cell treatment to help the graft settle

This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.

Palo Alto, California
NCT07634562Not yet recruiting· Phase 1/Phase 2
New Liver Transplant Treatment to Reduce Long-Term Rejection

This trial tests a new combination of radiation and antibody treatment for people receiving a liver transplant at Stanford. The goal is to help your new liver last longer by training your immune system to accept it while reducing the need for lifelong anti-rejection drugs.

Stanford, California
NCT05508009Recruiting· Phase 1/Phase 2
Kidney transplant with donor-matched stem cell treatment

This early-phase trial tests a stem cell transplant from a donor who is an extremely close match, given to people who are about to receive a kidney transplant from the same donor. The goal is to improve how well the new kidney works by resetting the immune system to better accept the transplant.

Palo Alto, California
NCT05385432Recruiting· Phase 3
Kidney transplant induction therapy for sensitized patients

This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.

Tours
NCT05525507Recruiting· Phase 1
Test early immune-tolerance treatment for matched kidney transplant patients

This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.

Los Angeles, California

Hear when a new Living Donor Kidney Transplantation trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.